Longer to wait for full picture on Moderna's flu vaccine program

12 April 2023
moderna-logo-large

Concerns about Moderna’s (Nasdaq: MRNA) post-COVID strategy have sparked a share price slide, following an ambivalent analysis from the firm’s flu vaccine program.

The global rollout of the Spikevax coronavirus vaccine generated tens of billions in revenue for the biotech, money which has been  invested in further pipeline development.

The company’s flu vaccine is a major piece of that strategy, with executives anticipating a 2024 launch, just in time to offset declining Spikevax sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology